Innovation
How Should the World Pay for a COVID-19 Vaccine?
29 April 2020
Prof. Adrian Towse discusses the options for funding the development and manufacture of a vaccine, reflecting on their strengths and weaknesses, considering what may happen with…
The Digitalisation of Health Care During COVID-19: Consideration of the Long-Term Consequences
28 April 2020
The need for social distancing in light of COVID-19 has led to an unprecedented increase in reliance on digital technologies by both health care providers and…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
Research by OHE and the University of Washington into how uncertainty-related novel elements of value could be included in an Augmented Cost-Effectiveness Analysis has been published…
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
1 April 2020
A COVID-19 vaccine is needed now, but timelines (12-18 months) create large market risk. By the time a vaccine is ready, the crisis may have passed.…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
Adrian Towse presented evidence that transparency of process reduced corruption and improved competition. Evidence was, however, against price transparency for on-patent medicines. It will reduce access…
Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation
21 February 2020
People living in Middle and Low Income Countries (MLICs) do not get access to innovative treatments and new treatments meeting MLIC requirements do not come to…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
OHE Lunchtime Seminar with Alistair McGuire, 3rd February 2020. The seminar will present some preliminary thoughts on the promises offered by personalised medicine that it will…
Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries
29 October 2019
New research by the Office of Health Economics (OHE) concludes the proposed International Price Index effectively outsources pharmaceutical policy decisions to countries that “give the government…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
OHE, in collaboration with RAND Europe, University College London (UCL) and University of Manchester (UoM), has been awarded a new research grant from Cancer Research UK…